Following a decade of
successfully shaping market leaders across the rapidly evolving animal health
market, Fidelio Capital AB (Fidelio) announced the formation of Vimian –
a global and diversified group of innovation-driven companies operating in four
fast-growing animal health verticals. Headquartered in Stockholm, Sweden,
Vimian and its family of companies serve more than 15,000 customers in +70
countries, employ over 400 people and have a combined turnover of approximately €140 million.
Vimian and its family of companies cover four essential areas within animal
health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech.
All of these companies share a passion for making a positive
impact through improving animal health, by delivering solutions, products and
services to animals and veterinary professionals around the world.
“By establishing Vimian, we are creating a global platform with a clear
ambition to lead the ongoing transformation of the animal health market. With
Vimian, we are bringing together some of the most innovative, high-quality and
entrepreneurial businesses under one umbrella, to create a uniquely diversified
proposition of products and services across four high-growth animal health
verticals”, says Gabriel Fitzgerald, Founder and CEO of Fidelio.
The first building block of Vimian was laid in 2015, when Fidelio invested
in what was to become Nextmune, Vimian’s Specialty Pharma division. Since then,
Fidelio has continued to partner with entrepreneurs, management teams and
owners of market leading businesses within Diagnostics (Indical Bioscience),
Veterinary Services (VetFamily) and MedTech (Movora). To date, 20 companies
have joined the Vimian platform on its ongoing journey towards improving animal
health for better lives.
“With Vimian, we combine the strengths and capabilities of a global group
with the intimacy, speed and creativity of an owner-led business. By sharing
knowledge, insights and resources across our family of businesses, we create an
unmatched opportunity to accelerate innovation, talent acquisition and growth.
Together, we are able to reach over 15,000 veterinary clinics and 1,500 labs
globally, with exceptional science and technology throughout our four areas. We
all share a passion for making a positive impact through improving animal
health, and I look forward to an exciting journey ahead with the entire Vimian
team”, says Dr. Fredrik Ullman, CEO of Vimian (former CEO of Indical
Bioscience).
